Gross proceeds expected to include $60 million from a committed PIPE and up to $175 million held in trust Anticipated cash resources will fund eFFECTOR’s pipeline advancement through multiple clinical milestones Merger expected to be completed in third quarter of 2021; combined company expected to be listed on Nasdaq under the ticker “EFTR” Webcast to discuss the proposed transaction scheduled for Thursday, May 27th at 9:00 am ET SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- eF